JP2016515628A - 癌を治療するための複合薬 - Google Patents

癌を治療するための複合薬 Download PDF

Info

Publication number
JP2016515628A
JP2016515628A JP2016506653A JP2016506653A JP2016515628A JP 2016515628 A JP2016515628 A JP 2016515628A JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016506653 A JP2016506653 A JP 2016506653A JP 2016515628 A JP2016515628 A JP 2016515628A
Authority
JP
Japan
Prior art keywords
compound
administered
less
dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016506653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515628A5 (enExample
Inventor
クリストファー ジェイ． スウィーニー，
クリストファー ジェイ． スウィーニー，
フィリッピ ダブリュー． カントフ，
フィリッピ ダブリュー． カントフ，
Original Assignee
エグゼリクシス， インコーポレイテッド
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド, エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2016515628A publication Critical patent/JP2016515628A/ja
Publication of JP2016515628A5 publication Critical patent/JP2016515628A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016506653A 2013-04-04 2014-04-04 癌を治療するための複合薬 Pending JP2016515628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808516P 2013-04-04 2013-04-04
US61/808,516 2013-04-04
PCT/US2014/033008 WO2014165779A1 (en) 2013-04-04 2014-04-04 Drug combinations to treat cancer

Publications (2)

Publication Number Publication Date
JP2016515628A true JP2016515628A (ja) 2016-05-30
JP2016515628A5 JP2016515628A5 (enExample) 2017-05-25

Family

ID=50732309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506653A Pending JP2016515628A (ja) 2013-04-04 2014-04-04 癌を治療するための複合薬

Country Status (11)

Country Link
US (1) US20160082019A1 (enExample)
EP (1) EP2983639A1 (enExample)
JP (1) JP2016515628A (enExample)
KR (1) KR20150138268A (enExample)
CN (1) CN108472242A (enExample)
AU (1) AU2014248001A1 (enExample)
BR (1) BR112015025408A8 (enExample)
CA (1) CA2908815A1 (enExample)
HK (1) HK1221424A1 (enExample)
MX (1) MX2015014046A (enExample)
WO (1) WO2014165779A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059744A1 (ja) * 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI640509B (zh) 2011-02-10 2018-11-11 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
AU2015218236B2 (en) 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
BR112019015011A2 (pt) * 2017-01-20 2020-04-28 Exelixis Inc combinações de cabozantinibe e atezolizumabe para tratar câncer
WO2019143908A1 (en) * 2018-01-19 2019-07-25 Indiana University Research And Technology Corporation Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphorylation in cancer
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2012515220A (ja) * 2009-01-16 2012-07-05 エクセリクシス， インク． Ｎ−（４−｛［６，７−ビス（メチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドのリンゴ酸塩およびその結晶質形態
JP2013501731A (ja) * 2009-08-07 2013-01-17 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターの使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP2454238A1 (en) * 2009-07-17 2012-05-23 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
DK2621481T4 (da) * 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
CN103664778B (zh) * 2013-11-27 2017-04-05 苏州摩尔医药有限公司 一种抗肿瘤治疗药物卡博替尼的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010501575A (ja) * 2006-08-25 2010-01-21 クオウガル バイオテクノロジー，インコーポレイテッド 癌を治療するための方法及び組成物
JP2012082215A (ja) * 2006-08-25 2012-04-26 Cougar Biotechnology Inc 癌を治療するための方法及び組成物
JP2012515220A (ja) * 2009-01-16 2012-07-05 エクセリクシス， インク． Ｎ−（４−｛［６，７−ビス（メチルオキシ）キノリン−４−イル］オキシ｝フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドのリンゴ酸塩およびその結晶質形態
JP2013501731A (ja) * 2009-08-07 2013-01-17 エグゼリクシス， インコーポレイテッド ｃ−Ｍｅｔモジュレーターの使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXELIXIS PRESS RELEASE, 2012.03.05, [平成30年1月26日検索], インターネット <HTTP://IR.EXELIXIS.COM/PH, JPN6018003391, ISSN: 0003906181 *
FRONTIERS IN ENDOCRINOLOGY, 2012.05.31, VOL. 3, ARTICLE 73, P. 1-11, JPN6018003392, ISSN: 0003906182 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020059744A1 (ja) * 2018-09-18 2020-03-26 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
JPWO2020059744A1 (ja) * 2018-09-18 2021-08-30 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
JP7540946B2 (ja) 2018-09-18 2024-08-27 大鵬薬品工業株式会社 アシルチオウレア化合物とアビラテロンの併用療法
AU2019342447B2 (en) * 2018-09-18 2025-05-29 Taiho Pharmaceutical Co., Ltd. Combination therapy of acylthiourea compound and abiraterone

Also Published As

Publication number Publication date
AU2014248001A1 (en) 2015-11-19
WO2014165779A1 (en) 2014-10-09
MX2015014046A (es) 2016-05-16
BR112015025408A8 (pt) 2018-07-10
US20160082019A1 (en) 2016-03-24
CN108472242A (zh) 2018-08-31
EP2983639A1 (en) 2016-02-17
CA2908815A1 (en) 2014-10-09
BR112015025408A2 (pt) 2017-07-18
HK1221424A1 (zh) 2017-06-02
KR20150138268A (ko) 2015-12-09

Similar Documents

Publication Publication Date Title
US20160082019A1 (en) Drug Combinations to Treat Cancer
ES3031468T3 (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
US20260060971A1 (en) Methods of treating solid tumors having activation fgfr3 gene alterations
Von Falck et al. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET (/CT) in initial staging and therapy monitoring
Borson-Chazot et al. Guidelines for the management of differentiated thyroid carcinomas of vesicular origin: recommandations pour la prise en charge des cancers thyroïdiens différenciés de souche vésiculaire
JP2023116537A (ja) 非小細胞肺がんの治療に使用するためのオシメルチニブ
KR20140094597A (ko) 암 치료를 정량하는 방법
US20250090507A1 (en) Methods of Treating Cancer With a B-RAF Inhibitor
KR20200014903A (ko) 암을 치료하기 위한 액체 투여형
Soriano-García et al. Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/II
US20240058339A1 (en) Combination therapy for cancers with kras mutation
KR20260049617A (ko) Cu-64 psma i＆t 주사를 사용하여 인간 대상체에서 전립선암을 검출하는 방법
WO2023212071A1 (en) Combination and the use thereof
WO2023136837A1 (en) Use of tivozanib and durvalumab for treating hepatocellular carcinoma (hcc)
US11471457B2 (en) Method of treating epithelial growth factor receptor (EGFR) T790M-positive non-small cell lung cancer by administering a combination of a VEGFR-2 antibody and osimertinib
Huang et al. Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocol
WO2025104045A1 (en) Alectinib for the treatment of alk fusion-positive solid or cns tumours
US20250387523A1 (en) Combination therapy of radionuclide complex
Lin et al. Transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis
WO2021068867A1 (en) Combination therapy for cancers with kras mutation
WO2025117506A1 (en) Therapies for the treatment of inflammatory bowel disease
AU2024390210A1 (en) Therapies for the treatment of inflammatory bowel disease
TW202502394A (zh) 治療前列腺癌之方法
HK40105135A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
HK40124164A (zh) 治疗具有激活型fgfr3基因改变的实体瘤的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181026